Darzalex SC (daratumumab)

pCPA File Number: 23105

Negotiation Status:

Under consideration for negotiation

Indication(s):

in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Sponsor/Manufacturer:

Janssen Inc.

CDA-AMC Project Number:

PC0388-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable